Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

Bebtelovimab is under clinical development by Eli Lilly and Co and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 ...

Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, ...

However, Lilly also treats cancer, plaque psoriasis, Alzheimer's disease, eczema, and more. While Novo and Lilly both make attractive opportunities, recent news has me more bullish on one of them.

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Peter Chin-Hong, an infectious disease specialist at UC San Francisco, said people should be on the lookout for the “Big Four”: three respiratory viruses currently moving through the U.S ...

Since then, I think it’s fair to say that most people have been nervous about the emergence of the next big infectious disease – be that a virus, bacterium, fungus or parasite. With COVID in ...

Some infectious diseases saw a huge surge in 2024, with the spread attributed in part to climate change, declining vaccination rates and the advent of new pathogen variants. The findings ...

Here’s what you should know. Meet the experts: Thomas Russo, MD, a professor and chief of infectious disease at the University at Buffalo in New York. What are the COVID symptoms to look for in ...

Eli Lilly announced FDA approval of Zepbound as the first prescription medicine for adults with moderate-to-severe obstructive sleep apnea. In addition, adults on Zepbound lost an average of 45 ...

Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market.